A multicenter observational study of Liposomal Irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON 2) (Prospective part)
Phase 4
Completed
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-UMIN000043939
- Lead Sponsor
- Sasebo Kyosai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
Patients 1. with active double cancers. 2. whom the doctor in-chief judged not to be indicated for this study. 3. who cannot submit ICs. 4. who have allergy for NAL-IRI. 5. who are contraindicated for NAL-IRI.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Response rate, disease control rate, progression-free survival
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the synergy of Liposomal Irinotecan and fluorouracil/leucovorin in pancreatic cancer treatment?
How does the Liposomal Irinotecan-fluorouracil/leucovorin regimen in NAPOLEON 2 compare to FOLFIRINOX in recurrent pancreatic cancer outcomes?
Which biomarkers correlate with response to Liposomal Irinotecan and fluorouracil/leucovorin in KRAS-mutant pancreatic cancer?
What adverse events are reported in the NAPOLEON 2 trial using Liposomal Irinotecan and fluorouracil/leucovorin?
How does the Liposomal Irinotecan formulation in NAPOLEON 2 compare to Onivyde in advanced pancreatic cancer treatment?